The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function
NCT06374641, Not applicable, Completed, University of Exeter
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function | ClinicalTrials.gov |
| NCT number | NCT06374641 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Exeter | ClinicalTrials.gov |
| Conditions | Exercise Performance, Cognitive Function | ClinicalTrials.gov |
| Interventions | Mitochondrial Substrate Supplement, Placebo Supplement | ClinicalTrials.gov |
| First posted | 2024-04-18 | ClinicalTrials.gov |
| Last updated | 2026-05-12 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Exercise Capacity | Day 15 and 16 | Exercise performance as measured by ramp incremental test (older group) or 3 minute all out test (young group) and intermittent exercise test. The ramp incremental cycling test is well-established for the determination of maximal oxygen uptake (VO2max) and gaseous exchange threshold, which are key markers of cardiorespiratory health and predictor of endurance exercise performance. The 3 minute all out test is commonly used to determine critical power and W'. The critical power represents the highest power output an individual can sustain while remaining in an aerobic steady state, and the W' represents the anaerobic capacity. The intermittent test consists of intermittent exercise in which 1 min of severe intensity exercise is alternated with 30 s of lower intensity exercise until the participant reaches their limit of tolerance. Time to exhaustion allows for assessment of exercise capacity. | ClinicalTrials.gov |
| Primary | VO2 kinetic response to exercise | Day 16 | The VO2 response measured during step test from unloaded to moderate intensity exercise. The participant will cycle against a low resistance and then the resistance on the pedals will be increased abruptly to provide a moderate-intensity work rate which will be maintained for 6 minutes. The VO2 response will then be examined from the onset of exercise to the attainment of a steady state. The VO2 responses to the three step tests will be averaged and modelled to provide information on the rate at which the muscle mitochondria use oxygen to supply energy to meet the demands of the exercise. The steady-state VO2 value for the imposed work rate also allows for the assessment of exercise economy. | ClinicalTrials.gov |
| Primary | Cognitive Function (Stroop test) | Day 15 | Cognitive function tested via Stroop test administered by computerised system. | ClinicalTrials.gov |
| Primary | Cognitive Function (decision reaction test) | Day 15 | Cognitive function tested via decision reaction test administered by computerised system. | ClinicalTrials.gov |
| Primary | Grip Strength | Day 15 | Grip strength measured by hand strength dynamometer. | ClinicalTrials.gov |
| Secondary | Capillary Blood Lactate | Before and after each step during the step test, and before and after every 2 exercise bouts during the intermittent exercise protocol. | Capillary Blood Lactate used during step tests and intermittent exercise tests to examine the production of lactate and inferred levels of muscle acidosis. | ClinicalTrials.gov |
| Secondary | Questionnaire 1 | Day 16 | To assess participant experience during the supplementation period and study protocol with regard to factors such as fatigue, stress, sleep and perceived effort. | ClinicalTrials.gov |
| Secondary | Questionnaire 2 | Day 15 | To assess participant experience of the supplement with regard to factors such as perceived effects, tolerance and taste. | ClinicalTrials.gov |
| Secondary | Venous Blood [Betaine] | Day 15 | Assessment of Venous Blood \[Betaine\]. | ClinicalTrials.gov |
| Secondary | Venous Blood [Choline] | Day 15 | Assessment of Venous Blood \[Choline\]. | ClinicalTrials.gov |
| Secondary | Venous blood [S-Adenosyl methionine] | Day 15 | Assessment of Venous Blood \[S-Adenosyl methionine\]. | ClinicalTrials.gov |
| Secondary | Venous blood [glucose]. | Day 15 | Assessment of Venous Blood \[glucose\]. | ClinicalTrials.gov |
| Secondary | Venous blood [insulin]. | Day 15 | Assessment of Venous Blood \[insulin\]. | ClinicalTrials.gov |
| Secondary | Venous blood [trimethylamine N-oxide]. | Day 15 | Assessment of Venous Blood \[triglycerides\]. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)